These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 37583422)

  • 61. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Yang Y; Luo H; Zheng XL; Ge H
    Clin Transl Oncol; 2021 Jun; 23(6):1117-1127. PubMed ID: 33211281
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.
    Liu Q; Fang Z; Liu M; Xu R; Yi F; Wei Y; Zeng L; Zhang W
    J Clin Pharm Ther; 2021 Dec; 46(6):1519-1530. PubMed ID: 34101874
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
    Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
    Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Predictive value of PD-L1 expression to the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer: A systematic review and meta-analysis.
    Qi Y; Yan X; Wang C; Cao H; Liu G
    Front Pharmacol; 2022; 13():1004821. PubMed ID: 36532783
    [No Abstract]   [Full Text] [Related]  

  • 65. The efficiency and safety of immune checkpoint inhibitors in the treatment of small cell lung cancer: a meta-analysis.
    Zhang S; Bi M
    Ann Palliat Med; 2020 Nov; 9(6):4081-4088. PubMed ID: 33302668
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Li LL; Yu CF; Xie HT; Chen Z; Jia BH; Xie FY; Cai YF; Xue P; Zhu SJ
    Cancer Med; 2023 May; 12(10):11211-11233. PubMed ID: 37161541
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Chemotherapy or chemo-immunotherapy as first-line treatment for extensive-stage small-cell lung cancer: a meta-analysis.
    Chen CY; Chen WC; Hung CM; Wei YF
    Immunotherapy; 2021 Oct; 13(14):1165-1177. PubMed ID: 34261336
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Assessing Potential Factors Influencing the Efficacy of Immune Checkpoint Inhibitors with Radiation in Advanced Non-Small-Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis.
    Xu H; Cao D; Zhou D; He A; Ge W; Xu X
    J Oncol; 2023; 2023():4477263. PubMed ID: 36688004
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy and safety of sintilimab in combination with chemotherapy for recurrent extensive-stage small cell lung cancer: a real-world retrospective study.
    Wang J; Liang S; Xu L; Kong Y; Seki N; Ganti AK; Neal JW; Li J; Xu F; Li K; Xu Y; Wu L; Chen B
    J Thorac Dis; 2024 Jun; 16(6):3897-3908. PubMed ID: 38983156
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Safety and efficacy of retreatment with immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis.
    Cai Z; Zhan P; Song Y; Liu H; Lv T
    Transl Lung Cancer Res; 2022 Aug; 11(8):1555-1566. PubMed ID: 36090645
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review.
    Wang T; Li Y; Zheng X
    BMC Health Serv Res; 2023 Jun; 23(1):691. PubMed ID: 37365540
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis.
    Li J; Chen Y; Hu F; Qiang H; Chang Q; Qian J; Shen Y; Cai Y; Chu T
    Front Oncol; 2022; 12():1001503. PubMed ID: 36523992
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Evaluation of Efficacy and Safety in First-Line Treatment Methods for Extensive-Stage Small Cell Lung Cancer: A Comprehensive Comparative Study of Chemotherapy, Targeted Therapy Combined With Chemotherapy, and Immunotherapy Combined With Chemotherapy.
    Zhang T; Tao L; Chen Y; Zhang S; Liu Y; Li Y; Wang R
    Clin Respir J; 2024 Aug; 18(8):e13819. PubMed ID: 39118429
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Rational application of the first-line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta-analysis.
    Cao R; Ma JT; Zhang SL; Sun L; Liu Y; Zhang XY; Jing W; Huang LT; Han CB
    Cancer Med; 2019 Sep; 8(11):5033-5046. PubMed ID: 31297962
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparison of Efficacy and Safety between Immune Checkpoint Inhibitors and Targeted Drugs in Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Su C; Liao Z; Wang Z; Pei Y; Li W; Liu J
    Comb Chem High Throughput Screen; 2024 Jun; ():. PubMed ID: 38920069
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study.
    Xie J; Chen M; Han H; Xu K; Qiu G; Lin X; Song Y; Ye J; Lv T; Zhan P
    Thorac Cancer; 2023 May; 14(15):1327-1338. PubMed ID: 37005095
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinical outcomes of extensive-stage small cell lung cancer patients treated with thoracic radiotherapy at different times and fractionations.
    Han J; Fu C; Li B
    Radiat Oncol; 2021 Mar; 16(1):47. PubMed ID: 33663551
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Assessing the Relationship Between Liver Metastases and the Survival of Patients With Non-Small Cell Lung Cancer After Immune Checkpoint Inhibitors Treatment: A Systematic Review and Meta-Analysis.
    Xu H; Ming P; Zhao Z; Zhao N; Zhou D; Tang X; Cao D
    Integr Cancer Ther; 2023; 22():15347354231164584. PubMed ID: 36998207
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Current status and future perspectives of immune checkpoint inhibitors in extensive-stage small cell lung cancer.
    Liu X; Xing H; Liu B
    Am J Cancer Res; 2022; 12(6):2447-2464. PubMed ID: 35812062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.